vs

Side-by-side financial comparison of GRAFTECH INTERNATIONAL LTD (EAF) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.

GRAFTECH INTERNATIONAL LTD is the larger business by last-quarter revenue ($125.1M vs $103.7M, roughly 1.2× Twist Bioscience Corp). Twist Bioscience Corp runs the higher net margin — -29.4% vs -34.6%, a 5.2% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 11.9%). GRAFTECH INTERNATIONAL LTD produced more free cash flow last quarter ($-27.1M vs $-34.8M).

GrafTech International Ltd. is a manufacturer of graphite electrodes and petroleum coke, which are essential for the production of electric arc furnace steel and other metals. Headquartered in Brooklyn Heights, Ohio, it has manufacturing facilities in Calais, France;Pamplona, Spain; Monterrey, Mexico; and St. Marys, Pennsylvania.

Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.

EAF vs TWST — Head-to-Head

Bigger by revenue
EAF
EAF
1.2× larger
EAF
$125.1M
$103.7M
TWST
Growing faster (revenue YoY)
TWST
TWST
+5.0% gap
TWST
16.9%
11.9%
EAF
Higher net margin
TWST
TWST
5.2% more per $
TWST
-29.4%
-34.6%
EAF
More free cash flow
EAF
EAF
$7.7M more FCF
EAF
$-27.1M
$-34.8M
TWST

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
EAF
EAF
TWST
TWST
Revenue
$125.1M
$103.7M
Net Profit
$-43.3M
$-30.5M
Gross Margin
-7.8%
52.0%
Operating Margin
-31.7%
Net Margin
-34.6%
-29.4%
Revenue YoY
11.9%
16.9%
Net Profit YoY
-10.0%
3.4%
EPS (diluted)
$-0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EAF
EAF
TWST
TWST
Q1 26
$125.1M
Q4 25
$116.5M
$103.7M
Q3 25
$144.0M
Q2 25
$131.8M
Q1 25
$111.8M
Q4 24
$134.2M
Q3 24
$130.7M
Q2 24
$137.3M
Net Profit
EAF
EAF
TWST
TWST
Q1 26
$-43.3M
Q4 25
$-65.1M
$-30.5M
Q3 25
$-28.5M
Q2 25
$-86.9M
Q1 25
$-39.4M
Q4 24
$-49.5M
Q3 24
$-36.1M
Q2 24
$-14.8M
Gross Margin
EAF
EAF
TWST
TWST
Q1 26
-7.8%
Q4 25
-20.9%
52.0%
Q3 25
7.2%
Q2 25
0.0%
Q1 25
-1.5%
Q4 24
-7.8%
Q3 24
-9.2%
Q2 24
2.9%
Operating Margin
EAF
EAF
TWST
TWST
Q1 26
Q4 25
-33.6%
-31.7%
Q3 25
-3.6%
Q2 25
-11.0%
Q1 25
-16.3%
Q4 24
-18.6%
Q3 24
-20.1%
Q2 24
-2.0%
Net Margin
EAF
EAF
TWST
TWST
Q1 26
-34.6%
Q4 25
-55.9%
-29.4%
Q3 25
-19.8%
Q2 25
-65.9%
Q1 25
-35.2%
Q4 24
-36.9%
Q3 24
-27.6%
Q2 24
-10.7%
EPS (diluted)
EAF
EAF
TWST
TWST
Q1 26
Q4 25
$-6.86
$-0.50
Q3 25
$-1.10
Q2 25
$-0.34
Q1 25
$-0.15
Q4 24
$-3.51
Q3 24
$-1.40
Q2 24
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EAF
EAF
TWST
TWST
Cash + ST InvestmentsLiquidity on hand
$120.2M
$197.9M
Total DebtLower is stronger
$1.1B
Stockholders' EquityBook value
$456.1M
Total Assets
$997.2M
$638.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EAF
EAF
TWST
TWST
Q1 26
$120.2M
Q4 25
$197.9M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$120.7M
Total Debt
EAF
EAF
TWST
TWST
Q1 26
$1.1B
Q4 25
$1.1B
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$1.1B
Q4 24
$1.1B
Q3 24
$929.5M
Q2 24
$928.2M
Stockholders' Equity
EAF
EAF
TWST
TWST
Q1 26
Q4 25
$-259.6M
$456.1M
Q3 25
$-194.4M
Q2 25
$-168.4M
Q1 25
$-105.3M
Q4 24
$-78.9M
Q3 24
$-9.0M
Q2 24
$16.2M
Total Assets
EAF
EAF
TWST
TWST
Q1 26
$997.2M
Q4 25
$1.0B
$638.1M
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$1.2B
Q4 24
$1.2B
Q3 24
$1.1B
Q2 24
$1.2B
Debt / Equity
EAF
EAF
TWST
TWST
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
57.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EAF
EAF
TWST
TWST
Operating Cash FlowLast quarter
$-14.9M
$-24.8M
Free Cash FlowOCF − Capex
$-27.1M
$-34.8M
FCF MarginFCF / Revenue
-21.6%
-33.5%
Capex IntensityCapex / Revenue
9.7%
9.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-105.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EAF
EAF
TWST
TWST
Q1 26
$-14.9M
Q4 25
$-20.9M
$-24.8M
Q3 25
$24.7M
Q2 25
$-53.2M
Q1 25
$-32.2M
Q4 24
$-26.4M
Q3 24
$23.7M
Q2 24
$-36.9M
Free Cash Flow
EAF
EAF
TWST
TWST
Q1 26
$-27.1M
Q4 25
$-39.3M
$-34.8M
Q3 25
$18.4M
Q2 25
$-57.1M
Q1 25
$-42.5M
Q4 24
$-39.2M
Q3 24
$19.7M
Q2 24
$-43.8M
FCF Margin
EAF
EAF
TWST
TWST
Q1 26
-21.6%
Q4 25
-33.7%
-33.5%
Q3 25
12.8%
Q2 25
-43.3%
Q1 25
-38.0%
Q4 24
-29.2%
Q3 24
15.1%
Q2 24
-31.9%
Capex Intensity
EAF
EAF
TWST
TWST
Q1 26
9.7%
Q4 25
15.8%
9.6%
Q3 25
4.4%
Q2 25
3.0%
Q1 25
9.2%
Q4 24
9.5%
Q3 24
3.1%
Q2 24
5.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EAF
EAF

Segment breakdown not available.

TWST
TWST

Industrial Chemicals$37.2M36%
Diagnostics$35.3M34%
Food Or Agriculture$12.8M12%
Academic Research$12.2M12%
Health Care$6.1M6%

Related Comparisons